Athenex, Inc., today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share.

Investments in China life science set new records in all categories during 2018, reflecting the increasing development of the industry. And these numbers are spectacular even in comparison to an already strong 2017.

Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.

BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.

Athenex has performed well in early trading since its market debut. It has demonstrated growing revenues, and its underwriters chose to exercise their over-allotment options in full.